Wockhardt Limited (WOCKPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wockhardt Limited (WOCKPHARMA) has a cash flow conversion efficiency ratio of -0.005x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-220.00 Million ≈ $-2.38 Million USD) by net assets (Rs46.57 Billion ≈ $503.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See WOCKPHARMA equity financing ratio to measure how much of total assets are equity-financed.
Wockhardt Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Wockhardt Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Wockhardt Limited earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Wockhardt Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wockhardt Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhuzhou Smelter Group Co Ltd
SHG:600961
|
0.076x |
|
Stepstone Group Inc
NASDAQ:STEP
|
0.052x |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
-0.086x |
|
Bilfinger SE
XETRA:GBF
|
0.082x |
|
Rush Street Interactive Inc
NYSE:RSI
|
0.151x |
|
Linktel Technologies Co. Ltd. A
SHE:301205
|
0.003x |
|
Tofas Turk Otomobil Fabrikasi AS
IS:TOASO
|
-0.019x |
|
Hafnia Limited
NYSE:HAFN
|
0.051x |
Annual Cash Flow Conversion Efficiency for Wockhardt Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Wockhardt Limited from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see Wockhardt Limited (WOCKPHARMA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs46.57 Billion ≈ $503.64 Million |
Rs-220.00 Million ≈ $-2.38 Million |
-0.005x | -107.90% |
| 2024-03-31 | Rs36.62 Billion ≈ $396.03 Million |
Rs2.19 Billion ≈ $23.68 Million |
0.060x | +43.14% |
| 2023-03-31 | Rs36.62 Billion ≈ $396.03 Million |
Rs1.53 Billion ≈ $16.55 Million |
0.042x | -57.49% |
| 2022-03-31 | Rs42.02 Billion ≈ $454.43 Million |
Rs4.13 Billion ≈ $44.66 Million |
0.098x | +228.63% |
| 2021-03-31 | Rs37.60 Billion ≈ $406.66 Million |
Rs-2.87 Billion ≈ $-31.07 Million |
-0.076x | -136.00% |
| 2020-03-31 | Rs30.57 Billion ≈ $330.65 Million |
Rs6.49 Billion ≈ $70.18 Million |
0.212x | +247.89% |
| 2019-03-31 | Rs30.05 Billion ≈ $324.94 Million |
Rs1.83 Billion ≈ $19.83 Million |
0.061x | +185.08% |
| 2018-03-31 | Rs31.98 Billion ≈ $345.84 Million |
Rs684.40 Million ≈ $7.40 Million |
0.021x | +129.53% |
| 2017-03-31 | Rs37.19 Billion ≈ $402.16 Million |
Rs-2.69 Billion ≈ $-29.14 Million |
-0.072x | -539.46% |
| 2016-03-31 | Rs43.43 Billion ≈ $469.66 Million |
Rs716.10 Million ≈ $7.74 Million |
0.016x | -82.07% |
| 2015-03-31 | Rs38.59 Billion ≈ $417.37 Million |
Rs3.55 Billion ≈ $38.39 Million |
0.092x | -76.84% |
| 2014-03-31 | Rs37.18 Billion ≈ $402.05 Million |
Rs14.76 Billion ≈ $159.66 Million |
0.397x | -29.92% |
| 2013-03-31 | Rs27.04 Billion ≈ $292.45 Million |
Rs15.32 Billion ≈ $165.72 Million |
0.567x | -29.62% |
| 2012-03-31 | Rs14.71 Billion ≈ $159.09 Million |
Rs11.84 Billion ≈ $128.08 Million |
0.805x | +41.30% |
| 2011-03-31 | Rs11.26 Billion ≈ $121.82 Million |
Rs6.42 Billion ≈ $69.41 Million |
0.570x | +347.19% |
| 2010-03-31 | Rs8.35 Billion ≈ $90.33 Million |
Rs-1.93 Billion ≈ $-20.82 Million |
-0.231x | -288.42% |
| 2009-03-31 | Rs10.18 Billion ≈ $110.06 Million |
Rs1.25 Billion ≈ $13.46 Million |
0.122x | -58.70% |
| 2008-03-31 | Rs12.74 Billion ≈ $137.73 Million |
Rs3.77 Billion ≈ $40.79 Million |
0.296x | +67.51% |
| 2007-03-31 | Rs10.66 Billion ≈ $115.32 Million |
Rs1.89 Billion ≈ $20.39 Million |
0.177x | -29.49% |
| 2006-03-31 | Rs8.16 Billion ≈ $88.26 Million |
Rs2.05 Billion ≈ $22.13 Million |
0.251x | -22.04% |
| 2005-03-31 | Rs6.17 Billion ≈ $66.68 Million |
Rs1.98 Billion ≈ $21.45 Million |
0.322x | -- |
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH… Read more